Physician profile
Andre A Ettinger
NPI 1073608592
$2,330.01
in general payments reported to CMS, 2019-2025
27 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $116 · 2021: $155 · 2022: $302 · 2023: $316 · 2024: $839 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.56 | 2021-2024 | |
| Genzyme Corporation | $213.83 | 2019-2025 | |
| Novo Nordisk INC | $199.20 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $183.50 | 2024 | Freestyle Libre 3 |
| Teleflex LLC | $162.66 | 2024 | Urolift |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.46 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $157.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $146.93 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $97.05 | 2019-2025 | Veozah |
| Pfizer INC. | $89.54 | 2019-2025 | |
| Boston Scientific Corporation | $75.81 | 2021-2022 | |
| Exact Sciences Corporation | $60.19 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $51.81 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.72 | 2020-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $46.49 | 2025 | Breztri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $38.67 | 2025 | Tirosint, Flector, Licart |
| Idorsia Pharmaceuticals US INC | $37.86 | 2022 | |
| Vertiflex, INC. | $36.13 | 2019 | |
| Merck Sharp & Dohme LLC | $35.96 | 2019-2022 | |
| Globus Medical, INC. | $33.73 | 2024 | Simplify Cervical Artificial Disc |
| Novartis Pharmaceuticals Corporation | $33.01 | 2019 | |
| Chiesi USA, INC. | $32.09 | 2025 | Elfabrio |
| Teva Pharmaceuticals USA, INC. | $25.85 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.57 | 2021 | |
| Amicus Therapeutics, INC. | $20.85 | 2023 | Galafold |
| Amarin Pharma, INC. | $17.61 | 2020 | |
| Sumitomo Pharma America, INC. | $17.30 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Ettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.